Search
for
Sort by
Research 241–270 of 1000+
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- Kaempferol enhances hair growth by regulating JAK3/STAT6 and TGF-β/Smad signaling in human dermal papilla cells and a C57BL/6 mousemodel
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Case Report: Multimodal contact immunotherapy in alopecia areata: long-term clinical experience in the JAK inhibitor era
- A bald statement - Current approaches to manipulate miniaturisation focus only on promoting hair growth
- MiRNA-24 downregulates KLF6 affecting STAT3 protein expression and phosphorylation regulating melanogenesis in cashmere goat coat
- Hydroxychloroquine modulates the progression of experimentally induced benign prostatic hyperplasia in rats via targeting EGFR/ERK/STAT3 and AR/FOXO1/TRAIL pathways: computational and in vivo studies
- Effect of diode pumping solid state laser with wavelength 589 nm on gene expression of interlukine-2 and interferon-gamma Lowercase in human T-lymphocytes
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
- Novel drugs of United States Food and Drug Administration approved in 2024
- Ruxolitinib for the treatment of severe alopecia areata
- JAK inhibitors in dermatology: The promise of a new drug class
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- JAK inhibition decreases the autoimmune burden in Down syndrome
- JAK inhibition decreases the autoimmune burden in Down syndrome
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Janus Kinase inhibitors in dermatology: a review
- ROS-responsive hydrogel-delivered miR-665 targets STAT3 to alleviate inflammation and promote hair follicle regeneration in alopecia areata
- ROS-responsive hydrogel-delivered miR-665 targets STAT3 to alleviate inflammation and promote hair follicle regeneration in alopecia areata
- Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- Effectiveness of baricitinib in severe alopecia areata in real life: a retrospective study of 87 patients
- Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- Alopecia Areata: a Comprehensive Review of Pathogenesis and Management
- Tofacitinib therapy for children with severe alopecia areata
- Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata